|
1
|
Poddubnaya IV, Alekseev SM, Kaplanov KD, Lukavetskyy LM, Rekhtman GB, Dolai TK, Attili VSS, Bermúdez CD, Isaev AA, Chernyaeva EV, Ivanov RA. Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial. Hematol Oncol 2020; 38:67-73. [DOI: 10.1002/hon.2693] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 10/25/2019] [Accepted: 11/04/2019] [Indexed: 12/31/2022]
Affiliation(s)
| | | | | | - Les M. Lukavetskyy
- Hematology DepartmentInstitute of Blood Pathology and Transfusion Medicine NAMS of Ukraine Lviv Ukraine
| | | | - Tuphan K. Dolai
- Hematology DepartmentNRS Medical College and Hospital Kolkata India
| | - V. Satya Suresh Attili
- Department of Internal MedicineSVS Medical College, Mehabubnagar and Continental Hospitals Hyderabad India
| | | | | | | | | |
Collapse
|
|
2
|
Lila AM, Mazurov VI, Denisov LN, Nesmeyanova OB, Ilivanova EP, Eremeeva AV, Usacheva JV, Dokukina EA, Chernyaeva EV, Ivanov RA. A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study. Rheumatol Int 2019; 39:1537-1546. [DOI: 10.1007/s00296-019-04359-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Accepted: 06/28/2019] [Indexed: 12/19/2022]
|